GlassScriptPhysician profile
Ashley Day
NPI 1750637930
$4,943.93
in general payments reported to CMS, 2019-2025
37 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,257 · 2022: $793 · 2023: $1,387 · 2024: $912 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Education: $44.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.24 |
| Education | $44.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $879.46 | 2021-2025 | |
| Pfizer INC. | $537.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $432.05 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $370.59 | 2021-2023 | Monjuvi, Jakafi |
| Seagen INC. | $365.42 | 2021-2023 | Tukysa |
| Genzyme Corporation | $310.39 | 2021-2025 | |
| Daiichi Sankyo INC. | $292.09 | 2022-2024 | Enhertu |
| Mirati Therapeutics, INC. | $271.83 | 2023-2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $203.78 | 2021-2025 | Reblozyl, Opdivo |
| Astellas Pharma US INC | $155.67 | 2022-2025 | Xospata, Vyloy, Padcev |
| Genentech USA, INC. | $139.94 | 2021-2023 | Lunsumio |
| Janssen Biotech, INC. | $113.03 | 2021-2024 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $100.85 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $94.27 | 2022-2023 | Xpovio |
| Amgen INC. | $92.98 | 2021-2023 | Lumakras |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.53 | 2021-2023 | Imfinzi |
| Abbvie INC. | $44.10 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.59 | 2021-2023 | |
| Exelixis INC. | $38.39 | 2025 | Cabometyx |
| Agios Pharmaceuticals, INC. | $36.90 | 2025 | Pyrukynd |
| Morphosys, US INC. | $30.42 | 2022 | |
| Epizyme, INC. | $28.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.66 | 2022 | |
| Emmaus Medical, INC. | $21.33 | 2023 | Endari |
| Lilly USA, LLC | $19.56 | 2025 | Jaypirca, Verzenio |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Array Biopharma INC | $18.46 | 2024 | Lorbrena, Braftovi, Mektovi |
| Taiho Oncology, INC. | $17.90 | 2023 | |
| Celgene Corporation | $16.78 | 2024 | Reblozyl |
| Alnylam Pharmaceuticals INC. | $16.29 | 2025 | Givlaari |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Sanofi-Aventis U.S. LLC | $14.79 | 2021 | |
| Acceleron Pharma, INC. | $14.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.69 | 2022 | |
| Genmab U.S., INC. | $14.45 | 2024 | Epkinly |
| Cti Biopharma Corp. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.